Company Overview
Company Type: Private Company
Company Status: Operating Subsidiary
Website: www.biopharmaservices.com
Number of Employees: -
Year Founded: 2006
Total Amount Raised (CAD mm)†: -
Total Rounds of Funding**:-
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
BioPharma Services Inc., a contract research organization, conducts clinical research trials for pharmaceutical and biotechnology companies worldwide. It also provides phase I/IIa clinical trial, human abuse potential and liability, bioequivalence and bioavailability studies, data management, bioanalysis, medical writing, pharmacokinetic, biometric/CDISC, recruitment, laboratory, scientific and regulatory affair, and biostatistics and safety data analysis services. The company was founded in 2006 and is based in Toronto, Canada with clinical facilities in Creve Coeur, Missouri; and Toronto, Canada. As of September 10, 2021, BioPharma Services Inc. operates as a subsidiary of Think Research Corporation.


Financial Information (Currency: CAD, in mm)
Total Revenue
-
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Estimated Number of Employees
-
Net Debt
-
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
Abuzgaya, Fathi
Chairman and President
DiCarlo, Renzo 
Chief Executive Officer
Rossini, Wendy
Chief Financial Officer
Matthews, Brent
Chief Operating Officer
Trabelsi, Fethi 
Vice President of Scientific Affairs
Rose, Ilan T.
Vice President of Business Development and Project Management
Dessouki, Esmat
Chief Medical Officer
Yeghikyan, Levon
Head of US Clinical Site

Key Board Members
Name
Title
Abuzgaya, Fathi
Chairman and President
Saleh, Salah 
Director


Primary Industry Classification
Life Sciences Tools and Services


Primary Office Location
3668 Weston Road | Toronto, ON | M9L 1W2 | Canada

Parent Company
Think Research Corporation (TSXV:THNK)

Prior Investors
Kashima International Inc., Mahy Investments Ltd., Moske Investments Ltd., N & M Medical Enterprises Inc., Ola Kassim Medicine Professional Corporation


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Bioanalytical Laboratory Services
Bioanalytical Laboratory Services operates as a contract research organization that specializes in bioanalytical services in Canada. It offers research services for generic pharmaceutical and biotechnology companies specializing in method development, method validation, and analysis of biological samples for pre-clinical and clinical drug trials (BA/BE studies). The company provides small-molecule regulatory-compliant bioanalytical services for drugs and metabolites in a variety of matrices for discovery, pre-clinical, and clinical studies. It also offers mass spectrometry; specialized tests to naturopaths and physicians practicing integrated medicine; specialized coagulation testing; and clinical genetic testing services. The company is based in Toronto, Canada. As of August 16, 2016, Bioanalytical Laboratory Services operates as a subsidiary of BioPharma Services Inc.

United States and Canada
Life Sciences Tools and Services
-
-
-
BioPharma Services USA Inc.
BioPharma Services USA Inc. is a research and consulting services company. It is based in Columbia, Missouri.

United States and Canada
Research and Consulting Services
5.00
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Jul-15-2021
Sep-10-2021
Merger/Acquisition
Target
BioPharma Services Inc.
Think Research Corporation (TSXV:THNK)
Mahy Investments Ltd.,Moske Investments Ltd.,N & M Medical Enterprises Inc.,Ola Kassim Medicine Professional Corporation,Kashima International Inc.
40.91
Aug-16-2016
Aug-16-2016
Merger/Acquisition
Buyer
Bioanalytical Laboratory Services
BioPharma Services Inc.
LifeLabs Inc.
-
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Sep-20-2022
Client Announcements
BioPharma Services Inc. Signs Multiple New Contracts in the Third Quarter
Sep-10-2021
M&A Transaction Closings
Think Research Corporation (TSXV:THNK) completed the acquisition of BioPharma Services Inc. from Mahy Investments Ltd., Moske Investments Ltd., N & M Medical Enterprises Inc., Ola Kassim Medicine Professional Corporation and Kashima International Inc. for CAD 43.3 million.
Jul-15-2021
M&A Transaction Announcements
Think Research Corporation (TSXV:THNK) entered into a definitive agreement to acquire BioPharma Services Inc. from Mahy Investments Ltd., Moske Investments Ltd., N & M Medical Enterprises Inc., Ola Kassim Medicine Professional Corporation and Kashima International Inc. for CAD 44.6 million.
Jun-17-2021
Client Announcements
Diamond Therapeutics Contracts BioPharma Services for Phase 1 Clinical Trial
Jun-08-2020
Business Expansions
BioPharma Services, Inc. Relocates to Expanded Clinic Facility in St. Louis Mo Due to Covid-19

M&A Advisors
Blake, Cassels & Graydon LLP


Advisors
M&A Advisors
Blake, Cassels & Graydon LLP


Last 10 Investment Research Documents
No Investment Research returned. This can be caused by entitlement settings or your template settings.


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
Bioequivalence Studies and Bioanalytical Services, Research Data and Analysis Services


Recent Major Filings

Key Filings
Filed On
Company Name
Source
Form Type
Size
May-29-2018
BioPharma Services Inc.
SEDAR
News Releases
20 KB

Key Board Members Details
Name
Title
Phone
Fax
Email
Abuzgaya, Fathi
Chairman and President
-
-
-
Saleh, Salah 
Director
-
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Abuzgaya, Fathi
Chairman and President
-
-
-
DiCarlo, Renzo 
Chief Executive Officer
(905) 206-8887
-
rdicarlo@biopharmaservices.com
Rossini, Wendy
Chief Financial Officer
-
-
-
Matthews, Brent
Chief Operating Officer
-
-
-
Trabelsi, Fethi 
Vice President of Scientific Affairs
-
-

Rose, Ilan T.
Vice President of Business Development and Project Management
-
-
irose@biopharmaservices.com
Dessouki, Esmat
Chief Medical Officer
-
-
-
Yeghikyan, Levon
Head of US Clinical Site
-
-
-
* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
